Next-Gen Nanobodies With MoonLake's Jorge Santos Da Silva, Ph.D.
Business Of Biotech
00:00
The Dissatisfaction With the Treatment Paradigm and Dermatology Indications
I think what we've seen in the last years is clearly a better understanding of all these diseases work. The frustration comes from the fact that because you don't have a therapeutic solutions, these diseases take forever to be diagnosed. But now, as I say, with the IL-17 pathway, and especially with the ANF inhibition, there's real hope.
Transcript
Play full episode
